medigraphic.com
Colegio de Medicina Interna de México.

2007, Number 4

<< Back Next >>

Med Int Mex 2007; 23 (4)

Positron emission tomography

Coronel AOF, Serna MJA, Bourlon CR, Bourlon RMT, Gómez SMA

Language: Spanish
References: 18
Page: 293-301
PDF size: 621.32 Kb.


ABSTRACT

Any illness has a natural history which course is due to different biological processes. Dynamic process cannot obtain an image that reflects this activity, except we could make a metabolic determination and comparation with the rest of the physiological process. The positron emission tomography offers information of these processes and gives us a different point of view in comparison to the rest of the other image modalities. Its main objective is the production of images that illustrate the physiologic function at a molecular level of some specific process, thus it is used to carry out the measurement of different vital processes (metabolism of glucose, perfusion and flow on certain tissues, rates of receiving union of complexes ligand-receptor and the oxygen exchange). With these images we can distinguish between a normal to abnormal functional in some particular structures. In comparison with the traditional nuclear medicine, positron emission tomography uses radiotracers markers like carbon, oxygen, nitrogen and fluorine (basic elements of the biological substrates). These isotopes looks like the natural substrata like sugars, water, proteins and oxygen. This technique modifies the rate cost-benefit in oncology, neurology, and cardiology field, to patient treatment. Moreover proved the benefits: a) to diagnosticate diseases before structural changes take place; b) monitoring the treatment response; c) to avoid unnecessary surgical procedures, and d) detect a distant or hidden metastasis.


REFERENCES

  1. Phelps ME. Inaugural article: positron emission tomography provides molecular imaging of biological processes. Proc Natl Acad Sci USA 2000;97(16):9226-33.

  2. Schwaiger M, Weber W. Functional imaging: from anatomy to molecular imaging. Medica Mundi 2002;46(1):2-10.

  3. Brownell GL. A history of positron imaging [en línea]. 1999. Dirección URL: .

  4. Zanzonico P. Positron emission tomography: a review of basic principles, scanner design and performance, and current systems. Semin Nucl Med 2004;34(2):87-111.

  5. Detterbeck F, Vansteenkiste JF, Morris DE, Dooms CA, et al. Seeking a home for a PET, part 3: emerging applications of positron emission tomography imaging in the management of patients with lung cancer. Chest 2004;126:1656-66.

  6. Higashi K, Ueda Y, Arisaka Y, Sakuma T, et al. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med 2002;43:39-45.

  7. Vansteenkiste JF, Stroobants SG, Dupont PJ, De Leyn PR, et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in nonsmall-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol 1999;17:3201-6.

  8. Ahuja V, Coleman RE, Herndon J, Patz EF. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer 1998;83:918-24.

  9. Schelling M, Avril N, Nahrig J, Kuhn W, et al. Positron emision tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000;18:1689-95.

  10. Smith IC, Welch AE, Hutcheon AW, Millar ID, et al. Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000;18:1676-88.

  11. Wieder HA, Brucher BL, Zimmermann F, Becker K, et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 2004;22:900-8.

  12. Jerusalem G, Hustinx R, Beguin Y, Fillet G. PET scan imaging in oncology. Eur J Cancer 2003;39:1525-34.

  13. Rades D, Kuhnel G, Wildfang I, Borner AR, et al. Localised disease in cancer of unknown primary (CUP): the value of positron emisión tomography (PET) for individual therapeutic management. Ann Oncol 2001;12:1605-9.

  14. Hain SF. Positron emission tomography in cancer of the head and neck. Br J Oral Maxillofac Surg 2005;43:1-6.

  15. Travin MI, Bergmann SR. Assessment of myocardial viability. Semin Nucl Med 2005;35:2-16.

  16. Emond M, Mock MB, Davis KB, Fisher LD, et al. Long-term survival of medically treated patients in the Coronary Artery Surgery Study (CASS) registry. Circulation 1994;90:2645-57.

  17. Instituto Nacional de Estadística Geografía e Informática. Base de datos de defunciones INEGI/Secretaría de Salud. Dirección General de Información en Salud. SINAIS, 2003. Dirección URL: < http://sinais.salud.gob.mx/mortalidad/2003/ mortalidad_c05_2003.xls>

  18. Machac J. Cardiac positron emission tomography imaging. Semin Nucl Med 2005;35:17-36.




2020     |     www.medigraphic.com